propranolol has been researched along with Glycogen Storage Disease Type II in 1 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Glycogen Storage Disease Type II: An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol-treated mice had decreased weight gain (p<0." | 1.43 | A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease. ( Han, SO; Kishnani, PS; Koeberl, DD; Li, S; Pope, R; Steet, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, SO | 1 |
| Pope, R | 1 |
| Li, S | 1 |
| Kishnani, PS | 1 |
| Steet, R | 1 |
| Koeberl, DD | 1 |
1 other study available for propranolol and Glycogen Storage Disease Type II
| Article | Year |
|---|---|
A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Topics: Adrenergic beta-Antagonists; alpha-Glucosidases; Animals; Cells, Cultured; Drug Antagonism; Drug Eva | 2016 |